We are currently engaged in discussions with potential partners. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. PGAs have become the most widely prescribed glaucoma drug class. The most frequently prescribed PGA is once-daily latanoprost. Once damaged, the optic nerve cannot regenerate and thus damage to vision is permanent. This may occur as early as three to six months after initiating treatment with a PGA. Symptoms of dry eye include ocular discomfort, dryness, and visual disturbance. In Europe, Rhokiinsa® and Roclanda® are registered trademarks of ours. These trials may also provide early evidence of effectiveness. The resubmitted application also is subject to review before the FDA files it. See "—Post-Marketing Requirements" below. The requirements governing drug pricing vary widely from country to country. In addition, many states have adopted laws similar to the Federal Anti-Kickback Statute. Non-innovator products are also subject to an additional rebate. The fee is not deductible for U.S. federal income tax purposes. In 2014, the new E.U. Clinical Trial Regulation 546/2014 was enacted (the "Regulation"). It is important for companies to ensure they have a nominated data protection officer. These programs include an Illness and Injury Prevention Program and a Safety Committee. This could cause the trading price of our common stock to decline. Obtaining these approvals can be a time consuming and expensive process. If the clinical trials are unsuccessful, we could be required to abandon development." We depend on our ability to protect our proprietary technology. The patent positions of pharmaceutical products are often complex and uncertain. Litigation may be necessary to defend against these claims. It takes at least six months to obtain approval of the application for PTE. Our ability to become and remain profitable depends on our ability to generate revenue. We were incorporated and commenced active operations in the second quarter of 2005. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. We also have applications for regulatory approval pending. Our business may be negatively impacted by macroeconomic conditions. Any adverse determination in litigation could also subject us to significant liabilities.